Posts by holdings2017bb

Honouring Ahmed M Kathrada

This morning we wake up to the news, that one of the country’s foremost leaders, a true son of the African soil, Ahmed Mohammed Kathrada, Uncle Kathy, had departed our world. Uncle Kathy, as he was and will continue to be affectionately known to us at Aspen, was one of our country’s key architects of…

Read More

Aspen AstraZeneca Anaesthetics Portfolio Agreement

Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio (“the Transaction”). AstraZeneca’s anaesthetics portfolio comprises seven established medicines, namely Diprivan (general anaesthesia),…

Read More

Aspen demonstrates economic growth and specialized technologies contributions to Deputy President Cyril Ramaphosa

Port Elizabeth. JSE-listed Aspen, the largest pharmaceutical manufacturer in the southern hemisphere, earlier today hosted Deputy President Cyril Ramaphosa and Minister of Health Dr Aaron Motsoaledi at its Port Elizabeth-based flagship manufacturing site. The visit provided an opportunity to discuss Aspen’s economic growth and export contributions to South Africa, and to demonstrate its globally recognised…

Read More

Acquisition of rights to an anti-coagulant product from Novartis

Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with Novartis AG in terms of which it will acquire the rights to Mono-Embolex®, an injectable anti-coagulant, for a consideration of US$142.3 million. Mono-Embolex is a heparin based anti-coagulant sold in the same…

Read More

2014 Anti-retroviral tender results

Following the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Pharmacare Limited t/a Aspen Pharmacare) has been successful in winning a number of key products in the tender Aspen’s award included 25% of the Fixed…

Read More

Aspen acquires a stake in an IMF production facility in New Zealand

Aspen Holdings is pleased to announce that it has concluded a transaction to acquire a 50% shareholding in New Zealand New Milk Limited (“NZNM”), a producer of infant milk formula in Auckland, New Zealand. In terms of a supply agreement concluded between Aspen Global Incorporated and NZNM, long-term supply of infant milk formula for distribution…

Read More

Aspen’s half-year revenue increases to R12 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the six months ended 31 December 2013. Group Performance Revenue increased by 33% to R12.0 billion. Operating profit improved by 16% to R2.9 billion after absorbing transaction…

Read More

Aspen’s growth formula

On a recent holiday to Disney World with his family, Aspen Pharmacare CE Stephen Saad wandered into a pharmacy while his children enjoyed the rides. On a shelf he found Murine Clear Eyes, the eye drops made at Aspen’s Port Elizabeth plant. “About 2m-3m packs a month are sold around the world but it was…

Read More

Honouring Former President Nelson Mandela

Johannesburg, Friday 6 December 2013 – Today, as the world mourns the passing of one of its most outstanding citizens and South Africa’s former President, Nelson Rolihlahla Mandela, Aspen, joins the millions of people worldwide, in expressing its deepest condolences to the family and friends of this humble leader. Stephen Saad, Aspen Group Chief Executive…

Read More

Aspen concludes the acquisition of an API Business from MSD

01 October 2013 By : Shauneen Beukes 1 October 2013 Oss, the Netherlands – JSE Limited listed Aspen Holdings, the ninth largest generic pharmaceutical company in the world, has announced that the Aspen Group (“Aspen”), has finalised the acquisition of Active Pharmaceutical Ingredient (API) manufacturing operations and related businesses (“the API Business”) from MSD, known…

Read More

Aspen acquires GSK brands and manufacturing site for £700 million

Durban, South Africa: Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen, announced today that it will acquire from GlaxoSmithKline plc (“GSK”) the Arixtra and Fraxiparine/Fraxodi brands (“the Brands”) and business worldwide, except in China, Pakistan and India (“the Excluded Territories”) as well as a specialised sterile production site which manufactures the Brands at…

Read More

R5 million injection for Nelson Mandela Children’s hospital

Johannesburg: Aspen Pharmacare, a JSE-listed leading pharmaceutical company in the southern hemisphere, provided a financial injection towards the establishment of the Nelson Mandela Children’s Hospital at the inaugural Mandela Sports and Culture Day. Stephen Saad, Aspen Group Chief Executive together with the Minister of Health, Dr Aaron Motsoaledi last year raised R10 million through the…

Read More